In depth characterization of midbrain organoids derived from wild type iPSC lines

The ability to model human neurological tissues in vitro has been a major hurdle to effective drug development for neurological disorders. iPSC-derived brain organoids have emerged as a compelling solution to this problem as they have the potential to relevantly model the protein expression pattern and physiology of specific brain regions. Although many protocols now exist for the production of brain organoids, few attempts have been made to do an in-depth kinetic evaluation of expression of mature regiospecific markers of brain organoids. To address this, we differentiated midbrain-specific brain organoids from iPSC-lines derived from three apparently healthy individuals using a matrix-free, bioreactor method. We monitored the expression of midbrain-specific neuronal markers from 7 to 90-days using immunofluorescence and immunohistology. The organoids were further characterized using electron microscopy and RNA-seq. In addition to serving as a potential benchmark for the future evaluation of other differentiation protocols, the markers observed in this study can be useful as control parameters to identify and evaluate the disease phenotypes in midbrain organoid derived from patient iPSC-lines with genetic neurological disorders.

Automated summary

The ability to model human neurological tissues in vitro is crucial for drug development in neurological disorders. iPSC-derived brain organoids can effectively mimic protein expression patterns and physiology of specific brain regions. This study differentiated midbrain-specific brain organoids from iPSC-lines derived from healthy individuals using a matrix-free, bioreactor method. The expression of midbrain-specific neuronal markers was monitored from 7 to 90 days, and the organoids were further characterized using electron microscopy and RNA-seq. The findings provide potential benchmarks for evaluating differentiation protocols and identifying disease phenotypes in midbrain organoids derived from patient iPSC-lines with genetic neurological disorders.